(Q80464237)

English

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques

scientific article published on 01 September 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

0 references

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

9

object named as

Barton F Haynes

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Michael A Egan

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Siew Yen Chong

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Michael Hagen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Shakuntala Megati

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Eva B Schadeck

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Priscilla Piacente

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ben-Jiang Ma

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

David C Montefiori

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Zimra R Israel

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

John H Eldridge

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 September 2004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

number of pages

15

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

27-28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

3774-3788

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Taking toll: lipid A mimetics as adjuvants and immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Immunization of female cynomolgus macaques with a synthetic epitope of sperm-specific lactate dehydrogenase results in high antibody titers but does not reduce fertility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Mycobacterium tuberculosis-secreted protein antigens: immunogenicity in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) lyme vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Induction of Th2 cytokine expression for p27-specific IgA B cell responses after targeted lymph node immunization with simian immunodeficiency virus antigens in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.03.011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15315859%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80464237&oldid=1775325804"